Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Dr. Reddy's Laboratories Ltd ADR (NY: RDY ) 15.11 +0.02 (+0.13%) Official Closing Price Updated: 7:00 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Dr. Reddy's Laboratories Ltd ADR < Previous 1 2 3 4 5 6 Next > Dr. Reddy’s Q3 & 9M FY24 Financial Results January 31, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr Reddy's Laboratories: Q3 Earnings Insights January 30, 2024 Via Benzinga Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands January 03, 2024 From Dr. Reddy's Laboratories Ltd. Via Business Wire Is NYSE:RDY suited for quality investing? September 14, 2023 Exploring DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)'s quality characteristics. Via Chartmill Should you consider NYSE:RDY for quality investing? August 21, 2023 DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) may be suited for quality investing, we'll explore why in this article. Via Chartmill Chart Of The Day: What's Cooking At Dr. Reddy's Lab July 28, 2023 100% technical buy signals 12 new highs and up 10.76% in the last month 38.40+ Weighted Alpha Via Talk Markets Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index December 14, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS) December 06, 2023 From Coya Therapeutics, Inc. Via Business Wire 2 overlooked stocks that crushed earnings but traded lower November 20, 2023 As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results Via MarketBeat Exposures Product Safety Dr. Reddy’s Q2 FY24 Financial Results October 27, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Why Quality Investors Should Delve into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) for Investment Opportunities. October 24, 2023 Reasonable Growth, Debt Levels, and a High ROIC Make DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Appealing to Quality Investors. Via Chartmill Top 5 Health Care Stocks That May Fall Off A Cliff August 23, 2023 The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. Via Benzinga Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. August 10, 2023 From Dr. Reddy's Laboratories Ltd. Via Business Wire Dr. Reddy’s Q1 FY24 Financial Results July 26, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA July 12, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Why Are Journey Medical Shares Trading Lower Today? July 11, 2023 Journey Medical Corporation (NASDAQ: DERM) shares are trading lower after the company announced topline results from the two Phase 3 trials, evaluating Minocycline Hydrochloride Modified Release... Via Benzinga Drugmaker GSK: Becoming a Healthier Value Stock June 27, 2023 Up more than 25% in the last nine months, U.K. pharmaceutical company GSK PLC is slowly regaining favor with investors after the GSK lawsuit. Via MarketBeat Topics Lawsuit Exposures Financial Legal Why Are Journey Medical Shares Trading Higher Today June 13, 2023 Journey Medical Corporation (NASDAQ: DERM) announced topline data from the Phase 1 clinical trial assessing the impact of DFD-29 on the Via Benzinga Dr. Reddy’s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab June 05, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire The 3 Most Undervalued Value Stocks to Buy in June 2023 June 04, 2023 One positive aspect about broader market challenges is the rising opportunity in the best undervalued value stocks for June. Via InvestorPlace Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC May 13, 2023 Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr.... Via Talk Markets Dr. Reddy’s Q4 & FY23 Financial Results May 10, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S. May 05, 2023 From Dr. Reddy's Laboratories Ltd. Via Business Wire Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S. April 21, 2023 From Dr. Reddy's Laboratories Ltd. Via Business Wire Why Aditxt Shares Are Surging Today April 20, 2023 Aditxt, Inc. (NASDAQ: ADTX) stock is surging Thursday as it expands its portfolio to include innovative therapies for infectious diseases. Via Benzinga Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) Making Surprising Moves in Wednesday Session April 12, 2023 Via Investor Brand Network Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) Sets New 52-Week High in Monday Session April 10, 2023 Via Investor Brand Network Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development March 23, 2023 By David Willey, Benzinga Via TheNewswire.com Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development March 23, 2023 Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development Via News Direct Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development March 22, 2023 Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India. Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
